Cell-free DNA (cfDNA) is circulating fragments of DNA that is released from cells into the circulatory system throughout the body. Tumor cells also release DNA into the blood stream, which is called circulation-tumor DNA(ctDNA).
IMBdx Inc.’s AlphaLiquid® platform offers industry-leading ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection(AlphaLiquid® 10/100/500) to recurrence and minimal residual disease(MRD) monitoring (AlphaLiquid® Detect), and early stage screening (AlphaLiquid® Screening)
What is Liquid Biopsy?
Liquid biopsy uses body fluids such as blood, cerebrospinal fluid, pleural effusion and urine to analyze trace amounts of ctDNA shed by tumor cells. Analysis of ctDNA can yield clinically actionable information to identify druggable targets, monitor therapy response, detect recurrence or screen for early-stage cancer.
Unlike tissue biopsies which involve invasive surgical procedures to obtain tumor tissue, liquid biopsies are based on non-invasive collection of body fluids such as a simple blood draw.
Minimally Invasive Specimen Collection
Reflection of Tumor Heterogeneity
Mutation-based Therapy Matching
· Non-invasive procedures for repeat testing and real-time monitoring of tumor remission and progression
· Captures tumor heterogeneity for more effective precision therapy strategy
· ctDNA progression precedes radiological progression by a significant lead time, enabling earlier detection
Tissue Biopsy
Liquid Biopsy
Non-Invasiveness & Serial Testing
Tumor Heterogeneity
Therapy Response Monitoring
Recurrence & MRD Monitoring
Early Stage Detection & Screening
When are Liquid Biopsies recommended?
· When tumor tissue is difficult to obtain
· When patient is in treatment and requires response monitoring
· When patient is in treatment and requires examination of resistance mutations
· After surgery, to evaluate the need for adjuvant therapy
· After surgery, as a surveillance tool to detect recurrence earlier
· When screening for early-stage cancer
AlphaLiquid® Platform
The AlphaLiquid® platform provides industry-leading ctDNA-based precision diagnostics solutions across all stages of cancer for patients, survivors and high-risk individuals.
Clinical Use Cases
AlphaLiquid®10
AlphaLiquid®100
AlphaLiquid®500
AlphaLiquid®Detect
AlphaLiquid®Screening
Therapy Selection & Response
Biomarker Discovery
Recurrence & MRD Monitoring
Cancer Screening
Target Group
Solid tumor patients
Solid tumor patients
Solid tumor patients
Patients or survivors in need of recurrence monitoring
Asymptomatic & high-risk individuals
AlphaLiquid® Platform Our Technology
Cutting Edge Technology
Proprietary biochemistry for high efficiency cfDNA extraction and library preparation
The most widely adopted liquid biopsy platform in Korea
Industry Leading Performance
Patented bioinformatics engine for error-suppression
Machine-learning enabled pipeline for continued upgrades in genomic data analytics
Clinically Validated
Robustly validated across over 10,000 patient samples
Over 30 completed and ongoing clinical studies and 12 peer-reviewed publications to date
